19 June 2020 CatalYm will be presenting two abstracts identifying a novel immunoregulatory role for Growth-and-Differentiation Factor 15 (GDF-15) and its effective neutralisation by CTL-002 antibody in cancer at the American Association for Cancer Research (AACR) Virtual Annual Meeting II on 22-24 June. Tumor-derived GDF-15 suppresses T-lymphocyte recruitment… Read More
AI VIVO, a company combining systems pharmacology and artificial intelligence (AI) to accelerate drug discovery, has announced that its platform identified dexamethasoneas having high potential for the treatment of COVID-19 in April 2020. AI VIVO, a company combining systems pharmacology and artificial intelligence (AI) to accelerate… Read More
Avacta Group, in collaboration with the Centre for Virus Research at the University of Glasgow, has shown that Affimer reagents which bind to the SARS-COV-2 virus spike protein, prevent infection of human cells by a SARS-COV-2 model virus and therefore provide a potential therapy for COVID-19 infection. Avacta… Read More
Cobra Biologics will provide GMP manufacture of the adenovirus vector-based COVID-19 vaccine candidate AZD1222, previously known as ChAdOx1 n-CoV-19. Cobra Biologics, part of the Cognate BioServices family, an international CDMO for biologics and pharmaceuticals, has signed a supply agreement with AstraZeneca UK to provide GMP manufacture of the adenovirus vector-based… Read More
Novasep, viral vector producer, has signed a partnership with AstraZeneca for the production of the Oxford University COVID-19 vaccine. Novasep will produce the active substance of the vaccine in its Belgian facilities The partnership follows the agreement between AstraZeneca and the Inclusive Alliance for Vaccines (IAV), to supply… Read More
17 June 2020 This is the second tranche of growth capital loan signed with the European Investment Bank in May 2019. The new funds will be used for the development, manufacture and commercialisation of in vitro diagnostics for infectious diseases Mobidiag, a revenue generating, molecular diagnostics company with… Read More
02 June, 2020 The developer and manufacturer of innovative laboratory tools for process optimisation, safety and scale-up, has announced the appointment of a new General Manager and Senior Vice President of North American Operations. Mert Sahin has been appointed as General Manager and Senior Vice President of H.E.L… Read More
New antibody internalization advanced screening method provides greater speed & insight 26 May 2020 Sponsored by Sartorius Researchers abilities to improve the breadth of therapeutic antibodies have been aided by innovative technologies for antibody discovery, for instance, through humanization of mouse antibodies and phage display. However, advanced antibody… Read More
Oxford University and its spin-out company Vaccitech announced an agreement with UK based biopharmaceutical specialist AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate, currently being trialled by the University. With immediate effect, the partnership is said to allow for rapid vaccination… Read More
This article is sponsored by BC Platforms. Lung cancer ranks among the most prevalent and fatal cancers worldwide, prompting the need for improved treatment outcomes. Effective management relies on understanding tumour characteristics, including histology, clinical staging, and biomarkers. Despite progress in targeted therapies, ongoing research is… Read More
Innovative glycan imaging methods drive cancer biomarker discovery By Dr Richard Drake, Dr Anand Mehta and Dr Peggy Angel Volume 21 Issue 2 - Spring 2020 Glycosylation accounts for the majority of post-translational modifications (PTMs) of proteins, and changes in glycosylation are known to play a key role in disease… Read More
Cryo-EM accelerates drug discovery by delivering previously intractable structural insights By Hans Raaijmakers, et al. Cryo-electron microscopy (cryo-EM), a powerful biophysical technique that can analyse molecular assemblies, is changing the paradigm in structure-based drug design. As targets become more challenging, solving structures of drug target molecules or biologics becomes increasingly… Read More
Harnessing the modified proteome for increased diagnostic power By Dr David Bramwell, Dr Steven Laval and Dr Jane McLeod Relevant biomarkers are vitally important in personalised medicine, guiding patient matching to specific therapies for earlier, easier and more effective disease identification and treatment. Here we trace the expectations of ’omicsbased… Read More
Unlocking the potential of Extracellular Vesicles: from single molecules to novel therapeutics By Dr Anna Caballe and Dr Katarzyna Ginda-Makela As part of normal homeostasis, cells release different types of small-sized membrane vesicles to traffic analytes across membranes, communicate with other cells and remove unwanted cell content. These vesicles can… Read More
By Dr Steve Arlington and John Wise As part of its mission to help members anticipate and prepare for changes in the pharmaceutical industry, The Pistoia Alliance has developed a research paper which sets out to consider what the life science, biopharma R&D and healthcare ecosystem might look like in… Read More
Using Live-Cell Imaging Systems to Transform Perspectives in Drug Discovery By Helen Stewart-Miller and Dr Kate Tointon Live-cell imaging has transformed the study of cell behaviour and function. The technique allows researchers to monitor internal cell structures, interactions and processes in real-time, and over time. In drug discovery, understanding the… Read More